Skip to main content
. 2020 Jun 28;2020:9815016. doi: 10.1155/2020/9815016

Figure 3.

Figure 3

Clinical benefits achieved in the IMPROVE-IT trial (primary end point was a combination of CV death/major CV event and nonfatal stroke; #nonsignificant. There was no difference in CV death and unstable angina).